(Q38223271)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24965505%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

title

Aurora kinase inhibitor patents and agents in clinical testing: an update (2011 - 2013) (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24965505%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

0 references

Chun Hei Antonio Cheung

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24965505%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Mohane S. Coumar

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24965505%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

author name string

Sailu Sarvagalla

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24965505%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Jane Ying-Chieh Lee

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24965505%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Yi-Chun Huang

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24965505%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

language of work or name

English

0 references

publication date

26 June 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24965505%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Therapeutic Patents

21 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24965505%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

volume

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24965505%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24965505%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

page(s)

1021-1038

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24965505%20AND%20SRC:MED&resulttype=core&format=json

Aurora A, meiosis and mitosis

21 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.931374

Aurora-A: the maker and breaker of spindle poles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.931374

Drosophila Aurora-A kinase inhibits neuroblast self-renewal by regulating aPKC/Numb cortical polarity and spindle orientation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.931374

Asymmetric division of Drosophila neural stem cells: a basis for neural diversity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.931374

Control of daughter cell fates during asymmetric division: interaction of Numb and Notch

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.931374

Linking cell cycle to asymmetric division: Aurora-A phosphorylates the Par complex to regulate Numb localization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.931374

Chromosomal passengers and the (aurora) ABCs of mitosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.931374

Aurora-C kinase is a novel chromosomal passenger protein that can complement Aurora-B kinase function in mitotic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.931374

Constitutive phosphorylation of aurora-a on ser51 induces its stabilization and consequent overexpression in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.931374

Frequent overexpression of Aurora Kinase A in upper gastrointestinal adenocarcinomas correlates with potent antiapoptotic functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.931374

Roles of Aurora kinases in mitosis and tumorigenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.931374

Aurora kinase A is a target of Wnt/beta-catenin involved in multiple myeloma disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.931374

Analysis of Aurora kinase A expression in CD34(+) blast cells isolated from patients with myelodysplastic syndromes and acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.931374

Aurora kinase family: a new target for anticancer drug.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.931374

Aurora kinase inhibitors--rising stars in cancer therapeutics?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.931374

Advances in Aurora kinase inhibitor patents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.931374

Aurora kinase inhibitor patents and agents in clinical testing: an update (2009-10).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.931374

Aurora kinase inhibitors: progress towards the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.931374

Antimitotic agents for the treatment of patients with metastatic castrate-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.931374

The potential role of Aurora kinase inhibitors in haematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.931374

Update on Aurora Kinase Targeted Therapeutics in Oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.931374

MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.931374

In vitro evaluation of the Aurora kinase inhibitor VX-680 for Hepatoblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.931374

Preclinical validation of Aurora kinases-targeting drugs in osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.931374

Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.931374

Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.931374

Randomized phase II study of danusertib in patients with metastatic castration-resistant prostate cancer after docetaxel failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.931374

Targeting aurora kinases with danusertib (PHA-739358) inhibits growth of liver metastases from gastroenteropancreatic neuroendocrine tumors in an orthotopic xenograft model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.931374

Treatment of human pre-B acute lymphoblastic leukemia with the Aurora kinase inhibitor PHA-739358 (Danusertib)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.931374

Abcg2 overexpression represents a novel mechanism for acquired resistance to the multi-kinase inhibitor Danusertib in BCR-ABL-positive cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.931374

Preclinical pharmacokinetic/pharmacodynamic/efficacy relationships for alisertib, an investigational small-molecule inhibitor of Aurora A kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.931374

Phase I study of MLN8237--investigational Aurora A kinase inhibitor--in relapsed/refractory multiple myeloma, non-Hodgkin lymphoma and chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.931374

Cancer cell resistance to aurora kinase inhibitors: identification of novel targets for cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.931374

High chromosome number in hematological cancer cell lines is a negative predictor of response to the inhibition of Aurora B and C by GSK1070916.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.931374

Phase I, open-label, multicentre, dose-escalation, pharmacokinetic and pharmacodynamic trial of the oral aurora kinase inhibitor PF-03814735 in advanced solid tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.931374

An integrated genomic approach to identify predictive biomarkers of response to the aurora kinase inhibitor PF-03814735.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.931374

ENMD-2076, an oral inhibitor of angiogenic and proliferation kinases, has activity in recurrent, platinum resistant ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.931374

Predictive biomarkers of sensitivity to the aurora and angiogenic kinase inhibitor ENMD-2076 in preclinical breast cancer models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.931374

NCIC CTG IND.181: phase I study of AT9283 given as a weekly 24 hour infusion in advanced malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.931374

A phase I and pharmacodynamic study of AT9283, a small-molecule inhibitor of aurora kinases in patients with relapsed/refractory leukemia or myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.931374

A phase I schedule dependency study of the aurora kinase inhibitor MSC1992371A in combination with gemcitabine in patients with solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.931374

A small-molecule inhibitor targeting the mitotic spindle checkpoint impairs the growth of uterine leiomyosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.931374

Targeting GD2 ganglioside and aurora A kinase as a dual strategy leading to cell death in cultures of human neuroblastoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.931374

AMG 900, pan-Aurora kinase inhibitor, preferentially inhibits the proliferation of breast cancer cell lines with dysfunctional p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.931374

AMG 900, a small-molecule inhibitor of aurora kinases, potentiates the activity of microtubule-targeting agents in human metastatic breast cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.931374

KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.931374

HDAC inhibitors potentiate the activity of the BCR/ABL kinase inhibitor KW-2449 in imatinib-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.931374

Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.931374

In vitro and in vivo pharmacokinetic characterizations of AMG 900, an orally bioavailable small molecule inhibitor of aurora kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.931374

Development of o -Chlorophenyl Substituted Pyrimidines as Exceptionally Potent Aurora Kinase Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.931374

Inhibitors targeting mitosis: tales of how great drugs against a promising target were brought down by a flawed rationale

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.931374

Shining the light on aurora-a kinase as a drug target in pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.931374

A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.931374